JP2023537761A5 - - Google Patents

Info

Publication number
JP2023537761A5
JP2023537761A5 JP2023510447A JP2023510447A JP2023537761A5 JP 2023537761 A5 JP2023537761 A5 JP 2023537761A5 JP 2023510447 A JP2023510447 A JP 2023510447A JP 2023510447 A JP2023510447 A JP 2023510447A JP 2023537761 A5 JP2023537761 A5 JP 2023537761A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
sequence
tdp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023510447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072639 external-priority patent/WO2022034228A1/en
Publication of JP2023537761A publication Critical patent/JP2023537761A/ja
Publication of JP2023537761A5 publication Critical patent/JP2023537761A5/ja
Pending legal-status Critical Current

Links

JP2023510447A 2020-08-14 2021-08-13 ヒト化抗tdp-43結合分子およびその使用 Pending JP2023537761A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20191232.6 2020-08-14
EP20191232 2020-08-14
PCT/EP2021/072639 WO2022034228A1 (en) 2020-08-14 2021-08-13 Humanized anti-tdp-43 binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023537761A JP2023537761A (ja) 2023-09-05
JP2023537761A5 true JP2023537761A5 (https=) 2024-08-19

Family

ID=72139446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510447A Pending JP2023537761A (ja) 2020-08-14 2021-08-13 ヒト化抗tdp-43結合分子およびその使用

Country Status (7)

Country Link
US (1) US20230322908A1 (https=)
EP (1) EP4196162A1 (https=)
JP (1) JP2023537761A (https=)
CN (1) CN116615452A (https=)
AR (1) AR123254A1 (https=)
TW (1) TW202221026A (https=)
WO (1) WO2022034228A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107901A1 (en) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CA3243689A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized Anti-TDP-43 Bonding Molecules and Their Uses
US20260043816A1 (en) * 2022-04-08 2026-02-12 Ac Immune Sa Anti-TDP-43 Binding Molecules
EP4676596A1 (en) 2023-03-08 2026-01-14 AC Immune SA Anti-tdp-43 binding molecules and uses thereof
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2026013218A1 (en) * 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
US8940872B2 (en) * 2007-07-06 2015-01-27 Tokyo Metropolitan Institute Of Medical Science Antibody binding specifically to TDP-43 aggregate
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US9587014B2 (en) * 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
JP6325463B2 (ja) 2012-03-16 2018-05-16 コヴァジェン アクチェン ゲゼルシャフト 抗腫瘍活性を有する新規結合分子
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof

Similar Documents

Publication Publication Date Title
JP2023537761A5 (https=)
JP2025507569A5 (https=)
JP7306660B2 (ja) RGMa結合タンパク質及びその使用
JP7208157B2 (ja) 抗ソルチリン抗体及びその使用方法
EP1838348B1 (en) Humanized amyloid beta antibodies for use in improving cognition
TWI449535B (zh) 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途
JP2022533432A5 (https=)
CN108431044A (zh) 抗age抗体及其使用方法
TW201206479A (en) Immunotherapy regimes dependent on ApoE status
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
TW202110879A (zh) 抗tdp-43結合分子及其用途
CN105431203A (zh) 治疗性融合蛋白
AU2020394842A1 (en) Novel molecules for therapy and diagnosis
CN110997715A (zh) 用于治疗突触核蛋白病的组合物和方法
TWI799840B (zh) 靶向介白素-34之化合物及方法
TW202342519A (zh) 人源化抗tdp-43結合分子及其用途
JP2023528535A (ja) セリン413においてリン酸化されたタウを標的化する高親和性抗体
CN116348487A (zh) 抗淀粉样β抗体
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
JP2025513799A5 (https=)
Pepinsky et al. Production of a PEGylated Fab′ of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination
KR20250135225A (ko) 항-아밀로이드 β 프로토피브릴/올리고머 항체 및 이의 용도
AU2024342582A1 (en) Anti-tdp-43 antibodies and uses thereof
JP2024544076A (ja) 抗cd95lモノクローナル中和抗体
JP2024506391A (ja) タウを認識する抗体の使用方法